Biomedical ETF (512290) rose over 1.5%, and Antu biological rose exceeding 4%

Antu Biological, Changchun High -tech, Watson Biological and other many rose 4%, biomedical ETF (512290) rose over 1.5%, and the turnover exceeded 60 million yuan.

China Merchants Securities said that the overall pharmaceuticals have the lower limit of performance and valuation elasticity.On the one hand, the medical demand side will always have unclean demand, and medical insurance funding is growing to the industry with a bottom limit.On the other hand, the medical insurance behavior (with volume procurement) accelerate the survival of the fittest, forcing global innovation, and the company with excellent fundamentals after a round of valuation adjustment has gradually showed cost -effectiveness. It is recommended to pay attention to investment opportunities for biomedical ETF (512290).Last pharmaceutical enterprise.

- END -